Navigation Links
Scientists Discover Existing Diabetes Drug Reduces Sight-threatening Rise in Brain Pressure
Date:9/7/2017

Research led by the University of Birmingham, UK, published in Science Translational Medicine, shows that a GLP-1 receptor agonist drug, Exenatide, currently used to treat patients with Type II diabetes could be repurposed to treat raised brain pressure (1).

Raised brain pressure is common in emergency situations such as traumatic brain injury, hydrocephalus and stroke, and is also the cardinal feature of Idiopathic Intracranial Hypertension (IIH), which causes permanent vision loss in 25% of people (2) and additionally disabling daily headaches due to the severely raised brain pressure. The condition effects 20 per 100,000 obese women and incidence is rising in line with the global obesity epidemic.

The Birmingham researchers examined whether the GPL-1 receptor agonist exendin-4 could reduce intracranial pressure in an animal model of raised brain pressure, and found that exendin-4 reduces intracranial pressure both rapidly and dramatically.

Corresponding author Dr Alexandra Sinclair, of the University of Birmingham’s Institute of Metabolism and Systems Research, said: “Our findings show that exendin-4 reduces brain pressure within 10 minutes of dosing and by 44%, which is a greater extent than anything else we’ve tested before, and the treatment effects last at least 24 hours. There are currently no bespoke treatments for IIH, which mostly affects women in their 20s and 30s. The primary treatment in IIH is acetazolamide, but many patients deteriorate and remain unwell despite treatment and the drug also has such severe side effects that our previous trials have shown that 48 per cent of patients stop taking it.”

The Birmingham team will be moving forward rapidly to clinical trials.

Alexandra Sinclair commented: “Exenatide is a well-tolerated and widely used drug for the treatment of diabetes which means that these findings are rapidly translatable into a novel treatment strategy for IIH. They are also potentially game-changing for other conditions featuring raised brain pressure including stroke and brain trauma.”

Exenatide, a synthetic version of exendin-4, has received Orphan Drug Designation for the treatment of Idiopathic Intracranial Hypertension from the European Medicines Authority and the US Food & Drug Administration (4,5).

About Idiopathic Intracranial Hypertension

  • Idiopathic Intracranial Hypertension is a rare chronic condition, with an incidence in the general population of 1-2 per 100,000, rising to 20 per 100,000 in women who are obese. However the incidence is rising dramatically in line with the global obesity epidemic.
  • IIH is caused by raised intracranial pressure, resulting in chronic disabling daily headaches and optic nerve swelling leading to blindness in 25%

The University of Birmingham has entered into an option agreement with BioDome Partners LLC, a California based incubator, under which BioDome Partners has the exclusive right to secure an exclusive global license for technology and IP of The University pertaining to the use of Exenatide for the treatment of IIH as well as other indications.

Media enquiries
Dr Alexandra Sinclair is available for interview.
For further editorial information or to arrange a media interview, contact Ruth Ashton, Reputation and Communications Development Manager, University of Birmingham, at r.c.ashton(at)bham.ac.uk, +44 (0)121 414 8646, or +44 (0) 7989 558 041.

Investors
For further information about investment contact:

Artin Asadourian, Managing Partner, BioDome Partners, LLC at: artin(at)biodomepartners.com , or 818-288-6200.

Dr Jonathan Watkins, Head of IP Services, University of Birmingham, at j.watkins.1(at)bham.ac.uk, or +44 (0)121 414 9090.

About the University of Birmingham
The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, teachers and more than 5,000 international students from over 150 countries.

About BioDome Partners, LLC
BioDome Partners, LLC, headquartered in San Francisco CA, is a privately held biotech incubator partnering with leading research institutions and inventors to catalyze innovative new business ventures. BioDome Partners focuses on identifying novel break through therapies that can help serve markets with significant unmet needs.

References:
1. Botfield et al (2017). Glucagon-like peptide-1 receptor agonists as a therapeutic to reduce intracranial pressure. Science Translational Medicine.
2. Markey et al (2016). Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurol 15(1): 78-91.
3. From: https://nei.nih.gov/health/iih/intracranial, accessed 14 August 2017
4. European Medicines Agency, EU/3/16/1629, accessed 14 August 2017
5. U.S. FDA, Orphan Drug Designations and Approvals, accessed 14 August 2017

Read the full story at http://www.prweb.com/releases/2017/09/prweb14659458.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Research Team led by JCVI Scientists Uncover More Complexity and Detail in Southern African Genomic Diversity
2. NineSigma Announces Winners in $25,000 Sustainable Packaging Challenge in Conjunction With Scientists Without Borders and Partners
3. Highly lethal Ebola virus has diagnostic Achilles heel for biothreat detection, scientists say
4. A bright idea: Tiny injectable LEDs help neuroscientists study the brain
5. Scientists Find Way to Fast-Track Production of Stem Cells that Show Promise in Treating AMD
6. Scripps Research Institute Scientists Find Antibody that Transforms Bone Marrow Stem Cells Directly into Brain Cells
7. Scottish Scientists Lead This Years Life Science Discoveries
8. NYSCF scientists create personalized bone substitutes from skin cells
9. Biomarker could help scientists choose the right cell line when conducting stem cell experiments
10. Advancing Research to Therapies for Brain Tumors Conference Connects Academic Scientists to Industry Investors
11. Scientists to Meet with State and Federal Lawmakers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):